DiaSorin's Q2 Rebound: 4% Growth Returns, but 2026's Payoff Still Depends on a Clean Finish

Q2 Rebuilt the Recovery Story, but Not the Full Year

DiaSorin's second quarter reset the narrative, but it did not close the book on 2026.

The quarter mattered because it broke the weak-start-to-the-year pattern. Q2 revenue grew 4% at constant exchange rates, and shares rose 3.92% to $71.66. For a company defending a recovery thesis, that is the kind of response investors usually want: visible top-line improvement, not just optimism.

The first-half context still matters, though. H1 2026 revenues were €602 million, flat at CER, and Net profit for H1 2026 was €84 million, down 15%. That points to a reset, not a clean bill of health.

The next few quarters matter more than the relief move. On the positive side, profitability improved as growth returned: adjusted EBITDA margin for H1 2026 was 32% and Q2 EBITDA margin improved to 33%. The real test now is whether DiaSorin can turn one good quarter into a credible second-half run that supports its reaffirmed full-year guidance.

Why the Bull Case Has Substance

The key point is not simply that DiaSorin grew again, but where the growth came from. The rebound appears more durable because it was supported by U.S. immunodiagnostics returned to historical double-digit growth and other established business lines that already have customers and repeat-demand paths in place. That is different from a one-off shipment bump.

Installed base and U.S. demand are doing the heavy lifting

In diagnostics, the analyzer is the beachhead and the assays are the repeat revenue stream. DiaSorin's U.S. immunodiagnostics returned to historical double-digit growth, helped by the recovery of QuantiFERON sales, suggests the existing base is starting to work again after a slow first quarter.

That matters because platform conversion can improve the mix over time. Management is targeting 600 hospitals by end of 2026, which matters if the company can keep converting sites into ongoing test volume.

New platforms add a second ramp

Product launches also add a second wave of upside. The Liaison Plex platform is gaining strong market traction, with over 150 customers, and the vast majority of new placements choosing the Flex configuration. That matters because Flex is the higher-throughput setup, so recent wins are leaning toward the better part of the business.

LIAISON NES adds another path. The company received FDA clearance for the second Liaison NES assay (Group A Strep), completing the full panel and enabling commercialization, and no current pricing pressure observed in the U.S. market. If launches track as expected, that gives investors a clearer route from product readiness to revenue.

There were supporting signals elsewhere too, including Licensed Technologies €43M (+7%) at CER, but the clearest mechanism remains immunodiagnostics and platform conversion. Bears can still point to China and the Middle East faced ongoing challenges. That is fair. The bull case, though, is that DiaSorin's stronger markets are showing reuse of the installed base, better conversion potential, and new-product upside at the same time.

Where the Bear Case Still Stands

After the Q2 relief, the bear case is not about whether DiaSorin can bounce from a bad quarter. It is about whether the remaining weaknesses are temporary drags or signs that growth is still too fragile for a full rerating.

The weak spots that look cyclical

Some pressure may simply reflect cooldown after an unusually soft demand period. The Liaison MDX respiratory segment declined 20% in Q2, which fits a weak flu-season pattern. Management also expects improved cash generation as inventory levels normalize. If that happens, these pressures look more like fading bruises than lasting damage.

The weak spots that look more structural

China remains the tougher issue. Diasorin SpA (DSRLF)'s business in China continues to decline roughly 25% due to VBP pricing and local competition, with no expected improvement in H2. At that pace, investors are less likely to treat it as a simple cycle and more likely to see it as a lower contribution going forward.

The Middle East also remains uneven, adding to the message that regional recovery is not yet broad-based.

Margins improved, but cash flow still needs proof

Margins have improved, but full confidence still needs cash-flow follow-through. That is why the next few quarters matter so much: investors need to see whether DiaSorin can keep margins in check while demand normalizes.

For a true rerating, the likely checklist is straightforward: - The China drag remains contained and does not spread to the rest of the mix. - Cash generation improves as inventory levels normalize. - Margin discipline holds around the company's adjusted EBITDA margin of 32% to 33%.

Until then, DiaSorin looks like a company with real momentum, but still incomplete execution.

What Would Confirm the Turn From Here?

What matters now is whether DiaSorin can turn one good quarter into a believable second-half run. After a flat first half, the burden is on H2 to support the company's reaffirmed full-year guidance.

The catalyst chain

The sequence is straightforward: - Another quarter of growth, after Q2 revenue grew 4% at constant exchange rates. - Continued margin discipline, after Q2 EBITDA margin improved to 33%. - Clean execution around NES and PLEX system rollouts.

The signposts that matter

These are the operating tells that the rebound is becoming durable: - U.S. immunodiagnostics returned to historical double-digit growth holds up. - The Liaison Plex platform is gaining strong market traction, with over 150 customers keeps building future demand. - Respiratory weakness fades as the season normalizes. - China and the Middle East stop holding back the rest of the portfolio.

When the thesis weakens

Stay constructive only if growth and profitability keep improving together. If guidance slips, margin pressure returns, or platform rollout momentum fades, this may prove to be relief rather than a full rerating.